What is Genomind?
Genomind operates at the intersection of psychiatry, neurology, and genetics, aiming to unravel the underlying causes of neuropsychiatric disorders. Through its innovative pharmacogenetic testing, the company supports the development and application of personalized medicine, thereby enhancing patient outcomes. Founded by Dr. Ronald I. Dozoretz and co-founded by Dr. Jay Lombard, Genomind is driven by a commitment to improving mental health through scientific discovery and expert leadership in the field. The company's focus on precision medicine positions it as a key player in transforming psychiatric care.
How much funding has Genomind raised?
Genomind has raised a total of $92.2M across 8 funding rounds:
Series A
$20.9M
Other Financing Round
$5M
Private Equity
$6M
Other Financing Round
$17.9M
Series B
$31.9M
Multiple Rounds
$10.4M
Series A (2014): $21M with participation from Claritas Capital
Other Financing Round (2014): $5M led by Claritas Capital
Private Equity (2015): $6M supported by Claritas Capital
Other Financing Round (2016): $18M featuring Claritas Capital
Series B (2017): $31.9M backed by Silicon Valley Bank
Debt (2020): $1M with participation from PPP
Series C (2020): $4.5M, investors not publicly disclosed
Series D (2020): $4.9M supported by Claritas Capital
Key Investors in Genomind
Claritas Capital
Claritas Capital is an alternative investments firm specializing in venture capital and real estate, with a focus on healthcare and technology sectors. They provide investment capital to innovative founders and entrepreneurs.
Silicon Valley Bank
Silicon Valley Bank offers a comprehensive suite of financial services, including commercial and private banking, asset management, and investment services, primarily supporting technology and life science companies.
PPP
Public-Private Partnership
What's next for Genomind?
The substantial enterprise-level funding and recent strategic investment signal a strong trajectory for Genomind. This capital infusion is expected to fuel further research and development, expand the company's testing capabilities, and enhance its market reach. Genomind is poised to deepen its impact on personalized psychiatry, leveraging its genetic insights to guide treatment decisions and improve patient lives. The company's ongoing commitment to innovation suggests a future focused on broadening the application of pharmacogenetics in mental healthcare and solidifying its leadership in the precision medicine landscape.
See full Genomind company page
